{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:24:29Z","timestamp":1791235469069,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","award":["Clinical basics of imaging, including Whole Body Magnetic Resonance Imaging in Gaucher disease"],"award-info":[{"award-number":["Clinical basics of imaging, including Whole Body Magnetic Resonance Imaging in Gaucher disease"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemia, leptin and ghrelin impairments, hypolipidaemia, linear growth deceleration and growth hormone deficiency, delayed puberty, hypocalcaemia and vitamin D deficiency. Specific treatments for GD such as enzyme replacement therapy and substrate reduction therapy display significant effects on the metabolic profile of GD patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Main body of the abstract<\/jats:title>\n<jats:p>Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1. GD1 appears to facilitate the development of disorders of nutrition, glucose metabolism and vitamin D insufficiency. Metabolic and hormonal diseases may have a significant impact on the course of the underlying disease and patient quality of life.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Conditions relating to hormones and metabolism can be wide-ranging in GD1. Obtained findings were intrinsic to GD either as a deleterious process or a compensatory response and some changes detected may represent co-morbidities. Actively seeking and diagnosing endocrine and metabolic disorders are strongly recommended in GD1 patients to optimize healthcare.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1211-5","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T09:06:14Z","timestamp":1575277574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2116-4384","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Ka\u0142u\u017cna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-5402","authenticated-orcid":false,"given":"Isabella","family":"Trzeciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-8834","authenticated-orcid":false,"given":"Katarzyna","family":"Ziemnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-4127","authenticated-orcid":false,"given":"Maciej","family":"Machaczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7220","authenticated-orcid":false,"given":"Marek","family":"Rucha\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"9645","key":"1211_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372(9645):1263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(08)61522-6.","journal-title":"Lancet"},{"issue":"6","key":"1211_CR2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","volume":"72","author":"A Tylki-Szymanska","year":"2007","unstructured":"Tylki-Szymanska A, Czartoryska B, Vanier MT, Poorthuis BJ, Groener JA, Lugowska A, et al. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007;72(6):538\u201342. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00899.x.","journal-title":"Clin Genet"},{"issue":"1","key":"1211_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3109\/03009734.2011.641609","volume":"117","author":"M Machaczka","year":"2012","unstructured":"Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, et al. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci. 2012;117(1):28\u201334. https:\/\/doi.org\/10.3109\/03009734.2011.641609.","journal-title":"Ups J Med Sci"},{"issue":"1","key":"1211_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00005-014-0308-8","volume":"63","author":"M Machaczka","year":"2015","unstructured":"Machaczka M, Kampe Bjorkvall C, Wieremiejczyk J, Paucar Arce M, Myhr-Eriksson K, Klimkowska M, et al. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3. Arch Immunol Ther Exp (Warsz). 2015;63(1):65\u201371. https:\/\/doi.org\/10.1007\/s00005-014-0308-8.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"1211_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/03009734.2016.1158756","volume":"121","author":"N Sawicka-Gutaj","year":"2016","unstructured":"Sawicka-Gutaj N, Machaczka M, Kulinska-Niedziela I, Bernardczyk-Meller J, Gutaj P, Sowinski J, et al. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy. Ups J Med Sci. 2016;121(3):192\u20135. https:\/\/doi.org\/10.3109\/03009734.2016.1158756.","journal-title":"Ups J Med Sci"},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcmd.2016.10.011","volume":"68","author":"M Machaczka","year":"2018","unstructured":"Machaczka M, Paucar M, Bjorkvall CK, Smith NJC, Cox TM, Forsgren L, et al. Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. Blood Cells Mol Dis. 2018;68:86\u201392. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.011.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1211_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/0034-7167-2016-0434","volume":"71","author":"MK Breigeiron","year":"2018","unstructured":"Breigeiron MK, Moraes VDC, Coelho JC. Signs and symptoms in Gaucher Disease: priority nursing diagnoses. Rev Bras Enferm. 2018;71(1):104\u201310. https:\/\/doi.org\/10.1590\/0034-7167-2016-0434.","journal-title":"Rev Bras Enferm"},{"issue":"1","key":"1211_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcmd.2015.10.001","volume":"56","author":"P Giraldo","year":"2016","unstructured":"Giraldo P, Perez-Lopez J, Nunez R, de la Puebla RF, Luno E, Saura-Grau S, et al. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status. Blood Cells Mol Dis. 2016;56(1):23\u201330. https:\/\/doi.org\/10.1016\/j.bcmd.2015.10.001.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1211_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1006\/bcmd.1998.0172","volume":"24","author":"H Ida","year":"1998","unstructured":"Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis. 1998;24(1):73\u201381. https:\/\/doi.org\/10.1006\/bcmd.1998.0172.","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"1211_CR10","first-page":"565","volume":"86","author":"S Zevin","year":"1993","unstructured":"Zevin S, Abrahamov A, Hadas-Halpern I, Kannai R, Levy-Lahad E, Horowitz M, et al. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med. 1993;86(9):565\u201373.","journal-title":"Q J Med"},{"issue":"8938","key":"1211_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0140-6736(94)90462-6","volume":"344","author":"B Bembi","year":"1994","unstructured":"Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet. 1994;344(8938):1679\u201382.","journal-title":"Lancet"},{"issue":"2","key":"1211_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","volume":"151","author":"G Drelichman","year":"2007","unstructured":"Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr. 2007;151(2):197\u2013201. https:\/\/doi.org\/10.1016\/j.jpeds.2007.02.057.","journal-title":"J Pediatr"},{"issue":"6","key":"1211_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2223\/JPED.909","volume":"78","author":"MC Oliveira","year":"2002","unstructured":"Oliveira MC, Oliveira BM, Queiros E, Viana MB. Clinical and nutritional aspects of Gaucher disease: prospective study of 13 children at a single center. J Pediatr. 2002;78(6):517\u201322.","journal-title":"J Pediatr"},{"issue":"8","key":"1211_CR14","first-page":"647","volume":"94","author":"R Heitner","year":"2004","unstructured":"Heitner R, Arndt S, Levin JB. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study. S Afr Med J. 2004;94(8):647\u201351.","journal-title":"S Afr Med J"},{"issue":"1","key":"1211_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1743-7075-10-34","volume":"10","author":"D Doneda","year":"2013","unstructured":"Doneda D, Netto CB, Moulin CC, Schwartz IV. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond). 2013;10(1):34. https:\/\/doi.org\/10.1186\/1743-7075-10-34.","journal-title":"Nutr Metab (Lond)"},{"issue":"3","key":"1211_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","volume":"40","author":"M Langeveld","year":"2008","unstructured":"Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis. 2008;40(3):428\u201332. https:\/\/doi.org\/10.1016\/j.bcmd.2007.09.002.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"1211_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","volume":"103","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med. 1997;103(3):185\u201391.","journal-title":"Am J Med"},{"issue":"9","key":"1211_CR18","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1210\/jcem.80.9.7673407","volume":"80","author":"EP Corssmit","year":"1995","unstructured":"Corssmit EP, Hollak CE, Endert E, van Oers MH, Sauerwein HP, Romijn JA. Increased basal glucose production in type 1 Gaucher's disease. J Clin Endocrinol Metab. 1995;80(9):2653\u20137. https:\/\/doi.org\/10.1210\/jcem.80.9.7673407.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1211_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","volume":"38","author":"DJ Barton","year":"1989","unstructured":"Barton DJ, Ludman MD, Benkov K, Grabowski GA, LeLeiko NS. Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. Metabolism. 1989;38(12):1238\u201343.","journal-title":"Metabolism"},{"issue":"5","key":"1211_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","volume":"30","author":"P Grigorescu Sido","year":"2007","unstructured":"Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, et al. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. J Inherit Metab Dis. 2007;30(5):783\u20139. https:\/\/doi.org\/10.1007\/s10545-007-0621-z.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1211_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","volume":"46","author":"D Doneda","year":"2011","unstructured":"Doneda D, Lopes AL, Oliveira AR, Netto CB, Moulin CC, Schwartz IV. Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil. Blood Cells Mol Dis. 2011;46(1):42\u20136. https:\/\/doi.org\/10.1016\/j.bcmd.2010.10.008.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1211_CR22","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1038\/s41598-017-03054-8","volume":"7","author":"AE Hendricks","year":"2017","unstructured":"Hendricks AE, Bochukova EG, Marenne G, Keogh JM, Atanassova N, Bounds R, et al. Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity. Sci Rep. 2017;7(1):4394. https:\/\/doi.org\/10.1038\/s41598-017-03054-8.","journal-title":"Sci Rep"},{"issue":"2","key":"1211_CR23","first-page":"19","volume":"26","author":"G Wilcox","year":"2005","unstructured":"Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19\u201339.","journal-title":"Clin Biochem Rev"},{"key":"1211_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","volume":"183","author":"JD Tune","year":"2017","unstructured":"Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57\u201370. https:\/\/doi.org\/10.1016\/j.trsl.2017.01.001.","journal-title":"Transl Res"},{"issue":"7","key":"1211_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793\u2013801. https:\/\/doi.org\/10.1172\/JCI29069.","journal-title":"J Clin Invest"},{"issue":"3","key":"1211_CR26","first-page":"743","volume":"59","author":"M Szurkowska","year":"2005","unstructured":"Szurkowska M, Szafraniec K, Gilis-Januszewska A, Szybinski Z, Huszno B. Insulin resistance indices in population-based study and their predictive value in defining metabolic syndrome. Przegl Epidemiol. 2005;59(3):743\u201351.","journal-title":"Przegl Epidemiol"},{"key":"1211_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1476-511X-9-113","volume":"9","author":"M Fuller","year":"2010","unstructured":"Fuller M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis. 2010;9:113. https:\/\/doi.org\/10.1186\/1476-511X-9-113.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"1211_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.bcmd.2007.10.004","volume":"40","author":"PJ Meikle","year":"2008","unstructured":"Meikle PJ, Whitfield PD, Rozaklis T, Blacklock D, Duplock S, Elstein D, et al. Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cells Mol Dis. 2008;40(3):420\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2007.10.004.","journal-title":"Blood Cells Mol Dis"},{"issue":"1-2","key":"1211_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","volume":"389","author":"K Ghauharali-van der Vlugt","year":"2008","unstructured":"Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 2008;389(1-2):109\u201313. https:\/\/doi.org\/10.1016\/j.cca.2007.12.001.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1211_CR30","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.2002.282.1.E1","volume":"282","author":"PE Bickel","year":"2002","unstructured":"Bickel PE. Lipid rafts and insulin signaling. Am J Physiol Endocrinol Metab. 2002;282(1):E1\u2013E10. https:\/\/doi.org\/10.1152\/ajpendo.2002.282.1.E1.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"1211_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1248\/yakushi.127.579","volume":"127","author":"J Inokuchi","year":"2007","unstructured":"Inokuchi J. Insulin resistance as a membrane microdomain disorder. Yakugaku Zasshi. 2007;127(4):579\u201386.","journal-title":"Yakugaku Zasshi"},{"issue":"Suppl 1","key":"1211_CR32","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1007\/BF03375458","volume":"42","author":"A Melander","year":"1999","unstructured":"Melander A, Olsson J, Lindberg G, Salzman A, Howard T, Stang P, et al. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999;42(Suppl 1):A1\u2013A330. https:\/\/doi.org\/10.1007\/BF03375458.","journal-title":"Diabetologia"},{"issue":"5522","key":"1211_CR33","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1126\/science.292.5522.1728","volume":"292","author":"H Cho","year":"2001","unstructured":"Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728\u201331. https:\/\/doi.org\/10.1126\/science.292.5522.1728.","journal-title":"Science"},{"key":"1211_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bcmd.2016.10.010","volume":"68","author":"F Lorenz","year":"2018","unstructured":"Lorenz F, Pawlowicz E, Klimkowska M, Beshara S, Bulanda Brustad A, Skotnicki AB, et al. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells Mol Dis. 2018;68:35\u201342. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.010.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"1211_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1210\/jc.2007-1702","volume":"93","author":"M Langeveld","year":"2008","unstructured":"Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab. 2008;93(3):845\u201351. https:\/\/doi.org\/10.1210\/jc.2007-1702.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1211_CR36","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2337\/db06-1619","volume":"56","author":"JM Aerts","year":"2007","unstructured":"Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes. 2007;56(5):1341\u20139. https:\/\/doi.org\/10.2337\/db06-1619.","journal-title":"Diabetes"},{"issue":"3","key":"1211_CR37","doi-asserted-by":"publisher","first-page":"e4723","DOI":"10.1371\/journal.pone.0004723","volume":"4","author":"M van Eijk","year":"2009","unstructured":"van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, Dubbelhuis PF, et al. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One. 2009;4(3):e4723. https:\/\/doi.org\/10.1371\/journal.pone.0004723.","journal-title":"PLoS One"},{"issue":"1","key":"1211_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ymgme.2008.10.001","volume":"96","author":"SK Ucar","year":"2009","unstructured":"Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, et al. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight. Mol Genet Metab. 2009;96(1):50\u20131. https:\/\/doi.org\/10.1016\/j.ymgme.2008.10.001.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1211_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4183\/aeb.2015.180","volume":"11","author":"A Zimmermann","year":"2015","unstructured":"Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Nascu I, Popp RA, Zimmermann T, Weber MM. A Prospective Study of Insulin Resistance in Gaucher Disease Type 1 Patients with Normal Weight, under Enzyme Replacement Therapy. Acta Endocrinol. 2015;11(2):180\u20138. https:\/\/doi.org\/10.4183\/aeb.2015.180.","journal-title":"Acta Endocrinol"},{"issue":"5","key":"1211_CR40","first-page":"274","volume":"43","author":"LL Bennett","year":"2018","unstructured":"Bennett LL, Fellner C. Pharmacotherapy of Gaucher Disease: Current and Future Options. Pharm Ther. 2018;43(5):274\u2013309.","journal-title":"Pharm Ther"},{"issue":"3","key":"1211_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10545-012-9529-3","volume":"36","author":"A Zimmermann","year":"2013","unstructured":"Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, et al. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. J Inherit Metab Dis. 2013;36(3):555\u201363. https:\/\/doi.org\/10.1007\/s10545-012-9529-3.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1211_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bcmd.2012.11.004","volume":"50","author":"AS Thomas","year":"2013","unstructured":"Thomas AS, Mehta AB, Hughes DA. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 2013;50(3):212\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2012.11.004.","journal-title":"Blood Cells Mol Dis"},{"issue":"17","key":"1211_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0025-7753(03)73797-X","volume":"120","author":"P Alfonso","year":"2003","unstructured":"Alfonso P, Cenarro A, Perez-Calvo JI, Puzo J, Giralt M, Giraldo P, et al. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease. Med Clin (Barc). 2003;120(17):641\u20136.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"1211_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","volume":"204","author":"M de Fost","year":"2009","unstructured":"de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JE, de Groot E, et al. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis. 2009;204(1):267\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.08.027.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1211_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.atherosclerosis.2009.10.015","volume":"209","author":"J Puzo","year":"2010","unstructured":"Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy. Atherosclerosis. 2010;209(2):515\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.10.015.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1211_CR46","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.clnu.2014.08.010","volume":"34","author":"D Doneda","year":"2015","unstructured":"Doneda D, Lopes AL, Teixeira BC, Mittelstadt SD, Moulin CC, Schwartz IV. Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy. Clin Nutr. 2015;34(4):727\u201331. https:\/\/doi.org\/10.1016\/j.clnu.2014.08.010.","journal-title":"Clin Nutr"},{"issue":"4","key":"1211_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.15403\/jgld.2014.1121.254.zim","volume":"25","author":"A Zimmermann","year":"2016","unstructured":"Zimmermann A, Popp RA, Al-Khzouz C, Bucerzan S, Nascu I, Leucuta D, et al. Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5\/ABCG8 Gene Variants. J Gastrointestin Liver Dis. 2016;25(4):447\u201355. https:\/\/doi.org\/10.15403\/jgld.2014.1121.254.zim.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"1211_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2141.2010.08167.x","volume":"150","author":"IJ Cohen","year":"2010","unstructured":"Cohen IJ, Yaniv I, Baris H. Diagnosis of severe type 1 Gaucher's disease before irreversible damage occurs : is HDL cholesterol the answer? Br J Haematol. 2010;150(1):118\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08167.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"1211_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","volume":"34","author":"P Stein","year":"2011","unstructured":"Stein P, Yang R, Liu J, Pastores GM, Mistry PK. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis. 2011;34(2):429\u201337. https:\/\/doi.org\/10.1007\/s10545-010-9271-7.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1211_CR50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","volume":"33","author":"TH Taddei","year":"2010","unstructured":"Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, et al. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis. 2010;33(3):291\u2013300. https:\/\/doi.org\/10.1007\/s10545-010-9070-1.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1211_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2005.10.007","volume":"338","author":"H Zhou","year":"2005","unstructured":"Zhou H, Song X, Briggs M, Violand B, Salsgiver W, Gulve EA, et al. Adiponectin represses gluconeogenesis independent of insulin in hepatocytes. Biochem Biophys Res Commun. 2005;338(2):793\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2005.10.007.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1211_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00125-004-1609-y","volume":"48","author":"RB Ceddia","year":"2005","unstructured":"Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005;48(1):132\u20139. https:\/\/doi.org\/10.1007\/s00125-004-1609-y.","journal-title":"Diabetologia"},{"issue":"5","key":"1211_CR53","first-page":"430","volume":"18","author":"M Esfahani","year":"2015","unstructured":"Esfahani M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci. 2015;18(5):430\u201342.","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"1211_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79\u201383.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1211_CR55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2337\/diabetes.52.2.239","volume":"52","author":"O Tschritter","year":"2003","unstructured":"Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52(2):239\u201343.","journal-title":"Diabetes"},{"issue":"5","key":"1211_CR56","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1210\/jcem.86.5.7463","volume":"86","author":"C Weyer","year":"2001","unstructured":"Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930\u20135. https:\/\/doi.org\/10.1210\/jcem.86.5.7463.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1211_CR57","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.metabol.2006.10.014","volume":"56","author":"M Langeveld","year":"2007","unstructured":"Langeveld M, Scheij S, Dubbelhuis P, Hollak CE, Sauerwein HP, Simons P, et al. Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. Metabolism. 2007;56(3):314\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2006.10.014.","journal-title":"Metabolism"},{"issue":"2","key":"1211_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2005.07.004","volume":"2","author":"D Ren","year":"2005","unstructured":"Ren D, Li M, Duan C, Rui L. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab. 2005;2(2):95\u2013104. https:\/\/doi.org\/10.1016\/j.cmet.2005.07.004.","journal-title":"Cell Metab"},{"key":"1211_CR59","doi-asserted-by":"publisher","first-page":"518909","DOI":"10.1155\/2013\/518909","volume":"2013","author":"C Delporte","year":"2013","unstructured":"Delporte C. Structure and physiological actions of ghrelin. Scientifica (Cairo). 2013;2013:518909. https:\/\/doi.org\/10.1155\/2013\/518909.","journal-title":"Scientifica (Cairo)"},{"issue":"2","key":"1211_CR60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.clnu.2014.12.017","volume":"34","author":"M Agilli","year":"2015","unstructured":"Agilli M, Aydin FN, Kurt YG. Leptin levels in Gaucher disease type I patients: A methodological approach. Clin Nutr. 2015;34(2):328. https:\/\/doi.org\/10.1016\/j.clnu.2014.12.017.","journal-title":"Clin Nutr"},{"issue":"5","key":"1211_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/eje.0.1390528","volume":"139","author":"MG Riad-Gabriel","year":"1998","unstructured":"Riad-Gabriel MG, Jinagouda SD, Sharma A, Boyadjian R, Saad MF. Changes in plasma leptin during the menstrual cycle. Eur J Endocrinol. 1998;139(5):528\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1211_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00380-011-0156-y","volume":"27","author":"Y Takahashi","year":"2012","unstructured":"Takahashi Y, Satoh M, Tabuchi T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessel. 2012;27(4):337\u201343. https:\/\/doi.org\/10.1007\/s00380-011-0156-y.","journal-title":"Heart Vessel"},{"issue":"2","key":"1211_CR63","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3892\/etm.2014.1777","volume":"8","author":"RB Xiong","year":"2014","unstructured":"Xiong RB, Li Q, Wan WR, Guo JQ, Luo BD, Gan L. Effects and mechanisms of vitamin A and vitamin E on the levels of serum leptin and other related cytokines in rats with rheumatoid arthritis. Exp Ther Med. 2014;8(2):499\u2013504. https:\/\/doi.org\/10.3892\/etm.2014.1777.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1211_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997;23(2):201\u201312. https:\/\/doi.org\/10.1006\/bcmd.1997.0137.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"1211_CR65","first-page":"158","volume":"2","author":"R Kauli","year":"2000","unstructured":"Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy. Isr Med Assoc J. 2000;2(2):158\u201363.","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"1211_CR66","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s10545-007-0715-7","volume":"30","author":"M Langeveld","year":"2007","unstructured":"Langeveld M, Endert E, Wiersinga WM, Aerts JM, Hollak CE. Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J Inherit Metab Dis. 2007;30(6):985. https:\/\/doi.org\/10.1007\/s10545-007-0715-7.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1211_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1079\/NRR19900010","volume":"3","author":"RJ Ross","year":"1990","unstructured":"Ross RJ, Buchanan CR. Growth hormone secretion: its regulation and the influence of nutritional factors. Nutr Res Rev. 1990;3(1):143\u201362. https:\/\/doi.org\/10.1079\/NRR19900010.","journal-title":"Nutr Res Rev"},{"issue":"6","key":"1211_CR68","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160(6):603\u20138. https:\/\/doi.org\/10.1001\/archpedi.160.6.603.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"1211_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1203\/00006450-200207000-00020","volume":"52","author":"S Rite","year":"2002","unstructured":"Rite S, Baldellou A, Giraldo P, Labarta JI, Giralt M, Rubio-Felix D, et al. Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res. 2002;52(1):109\u201312. https:\/\/doi.org\/10.1203\/00006450-200207000-00020.","journal-title":"Pediatr Res"},{"issue":"1","key":"1211_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0022-3476(96)70203-2","volume":"129","author":"P Kaplan","year":"1996","unstructured":"Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr. 1996;129(1):149\u201353.","journal-title":"J Pediatr"},{"issue":"4 Suppl 5","key":"1211_CR71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl 5):4\u201314.","journal-title":"Semin Hematol"},{"issue":"Suppl 3","key":"1211_CR72","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1007\/s10545-009-9016-7","volume":"33","author":"G Biasucci","year":"2010","unstructured":"Biasucci G, Manfredi P. Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature? J Inherit Metab Dis. 2010;33(Suppl 3):S51\u20134. https:\/\/doi.org\/10.1007\/s10545-009-9016-7.","journal-title":"J Inherit Metab Dis"},{"key":"1211_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcmd.2016.11.014","volume":"68","author":"E Mendelsohn","year":"2018","unstructured":"Mendelsohn E, Meir A, Abrahamov A, Elstein D, Zimran A, Levy-Khademi F. Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center. Blood Cells Mol Dis. 2018;68:97\u20139. https:\/\/doi.org\/10.1016\/j.bcmd.2016.11.014.","journal-title":"Blood Cells Mol Dis"},{"issue":"4 Pt 1","key":"1211_CR74","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/0002-9378(95)91494-3","volume":"172","author":"S Granovsky-Grisaru","year":"1995","unstructured":"Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, Horowitz M, Abrahamov A, Zimran A. Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients. Am J Obstet Gynecol. 1995;172(4 Pt 1):1284\u201390.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"1211_CR75","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0026-0495(87)90168-5","volume":"36","author":"RA Gelfand","year":"1987","unstructured":"Gelfand RA, Hutchinson-Williams KA, Bonde AA, Castellino P, Sherwin RS. Catabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown. Metabolism. 1987;36(6):562\u20139.","journal-title":"Metabolism"},{"issue":"5","key":"1211_CR76","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ajh.21684","volume":"85","author":"SM Lo","year":"2010","unstructured":"Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol. 2010;85(5):340\u20135. https:\/\/doi.org\/10.1002\/ajh.21684.","journal-title":"Am J Hematol"},{"key":"1211_CR77","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bcmd.2017.06.003","volume":"68","author":"M Baldini","year":"2018","unstructured":"Baldini M, Casirati G, Ulivieri FM, Cassinerio E, Khouri Chalouhi K, Poggiali E, et al. Skeletal involvement in type 1 Gaucher disease: Not just bone mineral density. Blood Cells Mol Dis. 2018;68:148\u201352. https:\/\/doi.org\/10.1016\/j.bcmd.2017.06.003.","journal-title":"Blood Cells Mol Dis"},{"issue":"23-24","key":"1211_CR78","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","volume":"160","author":"P Mikosch","year":"2010","unstructured":"Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr. 2010;160(23-24):609\u201324. https:\/\/doi.org\/10.1007\/s10354-010-0841-y.","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"1211_CR79","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4081\/hr.2012.e21","volume":"4","author":"G Giuffrida","year":"2012","unstructured":"Giuffrida G, Cingari MR, Parrinello N, Romano A, Triolo A, Franceschino M, et al. Bone turnover markers in patients with type 1 Gaucher disease. Hematol Rep. 2012;4(4):e21. https:\/\/doi.org\/10.4081\/hr.2012.e21.","journal-title":"Hematol Rep"},{"issue":"7","key":"1211_CR80","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00277-015-2354-7","volume":"94","author":"F Vairo","year":"2015","unstructured":"Vairo F, Sperb-Ludwig F, Wilke M, Michellin-Tirelli K, Netto C, Neto EC, et al. Osteopontin: a potential biomarker of Gaucher disease. Ann Hematol. 2015;94(7):1119\u201325. https:\/\/doi.org\/10.1007\/s00277-015-2354-7.","journal-title":"Ann Hematol"},{"issue":"27","key":"1211_CR81","doi-asserted-by":"publisher","first-page":"76","DOI":"10.17944\/mkutfd.41900","volume":"7","author":"K Sultan","year":"2016","unstructured":"Sultan K, Do\u011fan M, Keziban AB, Kaan D, Nihat D, Nesrin C. Association of Gaucher'd Disease with hypoparathyroidism: co-incidence or a novel association? Mustafa Kemal \u00dcniv T\u0131p Derg. 2016;7(27):76\u20138.","journal-title":"Mustafa Kemal \u00dcniv T\u0131p Derg"},{"issue":"21","key":"1211_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/arsm-2015-0022","volume":"2","author":"D Tofolean","year":"2015","unstructured":"Tofolean D, Adam T, Mazilu L, Parepa I-R. A case of late diagnosis of Gaucher disease with lung involvement (case study). ARS Medica Tomitana. 2015;2(21):63\u20136.","journal-title":"ARS Medica Tomitana"},{"key":"1211_CR83","first-page":"500","volume":"810","author":"HA Bischoff-Ferrari","year":"2014","unstructured":"Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2014;810:500\u201325.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"1211_CR84","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4065\/mcp.2010.0138","volume":"85","author":"KA Kennel","year":"2010","unstructured":"Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010;85(8):752\u20137. https:\/\/doi.org\/10.4065\/mcp.2010.0138 quiz 7-8.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1211_CR85","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266\u201381. https:\/\/doi.org\/10.1056\/NEJMra070553.","journal-title":"N Engl J Med"},{"issue":"4","key":"1211_CR86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/nbu.12108","volume":"39","author":"A Spiro","year":"2014","unstructured":"Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. Nutr Bull. 2014;39(4):322\u201350. https:\/\/doi.org\/10.1111\/nbu.12108.","journal-title":"Nutr Bull"},{"issue":"3","key":"1211_CR87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","volume":"96","author":"P Mikosch","year":"2009","unstructured":"Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet Metab. 2009;96(3):113\u201320. https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.001.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1211_CR88","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/ajcn\/85.3.860","volume":"85","author":"E Hypponen","year":"2007","unstructured":"Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85(3):860\u20138. https:\/\/doi.org\/10.1093\/ajcn\/85.3.860.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"1211_CR89","first-page":"31","volume":"13","author":"MS Parisi","year":"2008","unstructured":"Parisi MS, Mastaglia SR, Bagur A, Goldstein G, Zeni SN, Oliveri B. Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. Eur J Med Res. 2008;13(1):31\u20138.","journal-title":"Eur J Med Res"},{"issue":"5","key":"1211_CR90","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","volume":"28","author":"G Ciana","year":"2005","unstructured":"Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005;28(5):723\u201332. https:\/\/doi.org\/10.1007\/s10545-005-0032-y.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1211_CR91","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","volume":"28","author":"R Schiffmann","year":"2002","unstructured":"Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis. 2002;28(2):288\u201396.","journal-title":"Blood Cells Mol Dis"},{"key":"1211_CR92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","volume":"68","author":"M Biegstraaten","year":"2018","unstructured":"Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203\u20138. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.008.","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"1211_CR93","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","volume":"138","author":"D Hughes","year":"2007","unstructured":"Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol. 2007;138(6):676\u201386. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06701.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"1211_CR94","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J\u00e9r\u00f4me Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2). https:\/\/doi.org\/10.3390\/ijms18020441.","journal-title":"International Journal of Molecular Sciences"},{"key":"1211_CR95","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fendo.2018.00246","volume":"9","author":"A Rusinska","year":"2018","unstructured":"Rusinska A, Pludowski P, Walczak M, Borszewska-Kornacka MK, Bossowski A, Chlebna-Sokol D, et al. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland-Recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist Consultants and Representatives of Scientific Societies-2018 Update. Front Endocrinol (Lausanne). 2018;9:246. https:\/\/doi.org\/10.3389\/fendo.2018.00246.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1211_CR96","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, et al. Gaucher Disease in Bone: From Pathophysiology to Practice. J Bone Miner Res. 2019;34(6):996\u20131013. https:\/\/doi.org\/10.1002\/jbmr.3734.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1211_CR97","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911\u201330. https:\/\/doi.org\/10.1210\/jc.2011-0385.","journal-title":"J Clin Endocrinol Metab"},{"key":"1211_CR98","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2147\/TCRM.S177480","volume":"14","author":"A Zimmermann","year":"2018","unstructured":"Zimmermann A, Popp RA, Rossmann H, Bucerzan S, Nascu I, Leucuta D, et al. Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1. Ther Clin Risk Manag. 2018;14:2069\u201380. https:\/\/doi.org\/10.2147\/TCRM.S177480.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"1211_CR99","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10067-010-1464-9","volume":"29","author":"A Greenwood","year":"2010","unstructured":"Greenwood A, Elstein D, Zimran A, Altarescu G. Effect of vitamin D receptor (VDR) genotypes on the risk for osteoporosis in type 1 Gaucher disease. Clin Rheumatol. 2010;29(9):1037\u201341. https:\/\/doi.org\/10.1007\/s10067-010-1464-9.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1211_CR100","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bcmd.2010.09.002","volume":"46","author":"M Lieblich","year":"2011","unstructured":"Lieblich M, Altarescu G, Zimran A, Elstein D. Vitamin D Receptor (VDR) polymorphic variants in patients with cancer and Gaucher disease. Blood Cells Mol Dis. 2011;46(1):92\u20134. https:\/\/doi.org\/10.1016\/j.bcmd.2010.09.002.","journal-title":"Blood Cells Mol Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1211-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T19:54:39Z","timestamp":1606766079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1211-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}